Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 6/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25834708 | 1.00 | MEN1 (0.56) | MEN1KMT2AEPHX2TLR2THRB | |
| SCHEMBL23696456 | 0.98 | MEN1 (0.58) | MEN1KMT2AEPHX2TLR2THRB | |
| SCHEMBL22856581 | 0.98 | MEN1 (0.58) | MEN1KMT2AEPHX2TLR2THRB | |
| SCHEMBL22837704 | 0.98 | MEN1 (0.58) | MEN1KMT2AEPHX2TLR2THRB | |
| SCHEMBL22837672 | 0.97 | MEN1 (0.55) | MEN1KMT2AEPHX2TLR2THRB | |
| SCHEMBL21107013 | 0.93 | MMP8 (0.49) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL22794783 | 0.93 | MMP8 (0.49) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL23567935 | 0.93 | KMT2A (0.59) | MEN1KMT2AEPHX2TLR2MAPT | |
| SCHEMBL21946252 | 0.93 | KMT2A (0.59) | MEN1KMT2AEPHX2TLR2MAPT | |
| SCHEMBL8404639 | 0.93 | KMT2A (0.59) | MEN1KMT2AEPHX2TLR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | MEN1 1209/4885KMT2A 1024/4885EPHX2 3254/4885 |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | MEN1 1209/4885KMT2A 1024/4885EPHX2 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.